HSBC Holdings’s Inovio Pharmaceuticals INO Stock Holding History

HSBC Holdings’s Portfolio INO Stock Details INO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-26,075	Closed	-$55.9K	–	2919
2025 Q2	$55.9K	Buy	+26,075	New	+$50K	﹤0.01%	2918
2022 Q3	–	Sell	-3,533	Closed	-$73K	–	3086
2022 Q2	$73K	Sell	3,533 -440	-11%	-$12.4K	﹤0.01%	3090
2022 Q1	$171K	Buy	3,973 +540	+16%	+$24.3K	﹤0.01%	3026
2021 Q4	$206K	Hold	3,433	–	–	﹤0.01%	3022
2021 Q3	$295K	Sell	3,433 -1,020	-23%	-$102K	﹤0.01%	2557
2021 Q2	$497K	Buy	4,453 +995	+29%	+$95.6K	﹤0.01%	2181
2021 Q1	$385K	Sell	3,458 -1,255	-27%	-$165K	﹤0.01%	2151
2020 Q4	$502K	Buy	4,713 +3,535	+300%	+$471K	﹤0.01%	2195
2020 Q3	$164K	Sell	1,178 -90	-7%	-$18.8K	﹤0.01%	2525
2020 Q2	$410K	Buy	+1,268	New	+$204K	﹤0.01%	1956
2017 Q1	–	Sell	-953	Closed	-$79K	–	2342
2016 Q4	$79K	Buy	+953	New	+$86.2K	﹤0.01%	2641

Other funds holding INO

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BCM

Boxer Capital Management San Diego, California $762M AUM 1,125.36% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

HSBC Holdings's INO Position: Q3 2025 in Review

HSBC Holdings sold out of Inovio Pharmaceuticals (INO) in Q3 2025, closing a stake of 26,075 shares — an estimated $55.9K sold.

HSBC Holdings first reported a position in INO in Q4 2016 and held it in 11 quarters. The position peaked at $502K in Q4 2020. 99 funds tracked by Wall St. Rank hold INO as of Q3 2025.

HSBC Holdings reported no remaining Inovio Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
HSBC Holdings sold 26,075 Inovio Pharmaceuticals shares in Q3 2025, an estimated $55.9K.
HSBC Holdings first reported a position in Inovio Pharmaceuticals in Q4 2016 and held it in 11 quarters.
HSBC Holdings's Inovio Pharmaceuticals position peaked at $502K in Q4 2020.
99 funds tracked by Wall St. Rank held Inovio Pharmaceuticals as of Q3 2025.

Based on HSBC Holdings's 13F filing for Q3 2025, filed 13 Nov 2025.